Bristol Myers Squibb's Phase 3 ALOFT-IPF trial shows that admilparant at 60 mg met its primary endpoint in adults with idiopathic pulmonary fibrosis.

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.